The UK’s competition authority has provisionally found pharma company Concordia abused its dominant position to overcharge the National Health Service by millions for an essential thyroid d
Generics firms Concordia and Actavis signed illegal agreements enabling high prices for a life-saving drug to be prolonged, the UK’s competition watchdog has alleged.
The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio